Dan Strange

Chief Technology Officer • Cellular Origins, A TTP Company

For 15 years, Dan has worked at the intersection of engineering and biology. Dan carried out his PhD at Cambridge University, designing and automating tissue engineering bioprocesses. He then moved to TTP where he worked with clients to invent, design, and develop medical devices for clients such as 3M and Allergan before joining TTP’s cell and gene group to focus on automation, tools and technologies for cell therapy manufacturing. He has been involved in the development of 5 modular manufacturing systems ranging from cell selection to expansion. Dan is an active member of various automation working groups and a founding member of the TTP Cambridge Cell and Gene community. He is passionate about finding solutions to scale cell therapy to the hundreds of thousands of patients that could benefit. 

Also Speaking

Jennifer Chow

Chief Executive Officer & Managing Director • Chimeric Therapeutics

Stuart Gibb

Scientific Strategy Lead • Terumo Blood and Cell Technologies

Ohad Karneili

Chief Executive Officer • Adva Biotechnology

Also Speaking


Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.


Find out more and apply to get involved at the briefings taking place at Advanced Therapies Week.